Isotretinoin embryopathy : An entity that can be avoided
Sociedad Argentina de Pediatría..
Isotretinoin is the most effective drug in the treatment of severe recalcitrant nodulocystic acne. However, treatment with this drug is associated with adverse effects, the most severe being teratogenesis. It has been estimated that 40% of pregnancies exposed to isotretinoin present spontaneous abortion and 35% develop embryopathy. We present the case of a newborn with a history of prenatal exposure to isotretinoin, a clinical entity that can be avoided, with severe congenital defects in the central nervous system and important facial dysmorphisms, with unfavorable clinical course.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
|---|---|
| Enthalten in: |
Archivos argentinos de pediatria - 116(2018), 2 vom: 01. Apr., Seite e303-e307 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Embriopatía por isotretinoína: Una entidad que puede evitarse |
|---|
| Beteiligte Personen: |
Cammarata-Scalisi, Francisco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Completed 29.08.2019 Date Revised 29.08.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.5546/aap.2018.e303 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM28213364X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM28213364X | ||
| 003 | DE-627 | ||
| 005 | 20231225033226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.5546/aap.2018.e303 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0940.xml |
| 035 | |a (DE-627)NLM28213364X | ||
| 035 | |a (NLM)29557621 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Cammarata-Scalisi, Francisco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Isotretinoin embryopathy |b An entity that can be avoided |
| 246 | 3 | 3 | |a Embriopatía por isotretinoína: Una entidad que puede evitarse |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.08.2019 | ||
| 500 | |a Date Revised 29.08.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Sociedad Argentina de Pediatría. | ||
| 520 | |a Isotretinoin is the most effective drug in the treatment of severe recalcitrant nodulocystic acne. However, treatment with this drug is associated with adverse effects, the most severe being teratogenesis. It has been estimated that 40% of pregnancies exposed to isotretinoin present spontaneous abortion and 35% develop embryopathy. We present the case of a newborn with a history of prenatal exposure to isotretinoin, a clinical entity that can be avoided, with severe congenital defects in the central nervous system and important facial dysmorphisms, with unfavorable clinical course | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Embryopathy | |
| 650 | 4 | |a Isotretinoin | |
| 650 | 4 | |a Teratogenesis | |
| 650 | 7 | |a Isotretinoin |2 NLM | |
| 650 | 7 | |a EH28UP18IF |2 NLM | |
| 700 | 1 | |a Nieves, Dairelis |e verfasserin |4 aut | |
| 700 | 1 | |a Avendaño, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Lacruz-Rengel, María A |e verfasserin |4 aut | |
| 700 | 1 | |a Alviárez, Karelys |e verfasserin |4 aut | |
| 700 | 1 | |a Dávila, Francys |e verfasserin |4 aut | |
| 700 | 1 | |a Yavuz, Izzet |e verfasserin |4 aut | |
| 700 | 1 | |a Callea, Michele |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archivos argentinos de pediatria |d 1945 |g 116(2018), 2 vom: 01. Apr., Seite e303-e307 |w (DE-627)NLM040810917 |x 1668-3501 |7 nnns |
| 773 | 1 | 8 | |g volume:116 |g year:2018 |g number:2 |g day:01 |g month:04 |g pages:e303-e307 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5546/aap.2018.e303 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 116 |j 2018 |e 2 |b 01 |c 04 |h e303-e307 | ||